AorTech reveals first human use of Elast-Eon

AorTech International has announced the first human use of its proprietary biostable polymer Elast-Eon as the header component and lead insulation for a novel neurostimulation pain management device.

AorTech estimates the combined header market to be some 3.5 million devices annually of which 85% are for cardiac pacing and the balance for neurostimulation use resulting in estimated combined header component manufacturing costs and sales in excess of $75m.

CEO Frank Maguire said, "AorTech became interested in the cardiac rhythm management and neurostimulation header market on the heels of the success of its Elast-Eon materials in pacing lead applications.

"Our proprietary header materials and E-RIM (small part reaction injection moulding) manufacturing process improves bond strengths reducing product failures and recalls while also improving manufacturing throughput resulting in significant cost savings for our customers.

"E-RIM and AorTech polymers are currently being qualified for use in a number of orthopaedic, cardiac surgery, cardiac rhythm management headers and vascular devices.

"AorTech expects that this programme will be a significant contributor to the growth of its component business in 2011 and beyond."

Story provided by StockMarketWire.com